透過您的圖書館登入
IP:3.129.13.201

並列摘要


Intravenous thrombolysis is still one of the most effective therapies for patients with acute ischemic stroke. Recombinant tissue-type plasminogen activator (rt-PA) has been approved for clinical use since 2002 in Taiwan. Previously, Taiwan Stroke Society has published the guidelines of intravenous thrombolysis for acute ischemic stroke patients in 2008 and 2013, respectively. Enhanced effort to increase intravenous rt-PA treatment for acute ischemic stroke patients in Taiwan can be observed, and the rate of treatment reached to 4-5% in recent years. However, the indication and treatment time of intravenous thrombolysis have been expanded recently. To provide the evidence-based recommendations, and standardize intravenous thrombolysis for acute ischemic stroke, the Taiwan Stroke Society Guideline Consensus Group revised the guideline. The guideline contains 5 issues, including intravenous rt-PA treatment for onset to needle time more than 3 hours, age over 80 years, mild or rapidly improving symptoms, pre-stroke use of anticoagulants, and probably endovascular thrombectomy for patients with large vessel occlusion.

被引用紀錄


陳右緯、鄭建興(2019)。急性缺血性腦中風靜脈血栓溶解治療台灣醫學23(6),722-727。https://doi.org/10.6320/FJM.201911_23(6).0004
楊曉倩、李榮真(2022)。照顧一位缺血性腦中風接受血栓溶解劑治療之護理經驗志為護理-慈濟護理雜誌21(6),119-128。https://www.airitilibrary.com/Article/Detail?DocID=16831624-N202303180008-00022

延伸閱讀